Home » Newsletters » BioWorld Science

BioWorld Science

May 28, 2002

View Archived Issues

ACH-126443 demonstrates clinical anti-HBV activity

Solvay requests withdrawal of Luvox NDA

New data on omalizumab presented at ATS 2002

Novel metalloproteinase inhibitors designed at DuPont

CDK4 inhibitors with antitumor activity prepared and tested at Lilly

Eisai presents novel AMPA/kainate receptor antagonists

Inhibitors of apo B secretion and their use in lipoprotein disorders

Applied Research Systems patents JNK inhibitors

PDE7 inhibitors useful for T-cell-related conditions

Neurogen claims the preparation and use of CRF1 ligands

Safety of continuous infusions of GEM-231 and effects on serum extracellular PKA levels

Novel epothilone examined for pharmacokinetic behavior in phase I trial

Clinical data for histone deacetylase inhibitor FR-901228 presented in Orlando

Phase I EMD-72000 results presented at ASCO

CKD-602 evaluated clinically as a treatment for solid tumors

MicardisPlus approved in E.U. for hypertension

Sosei licenses KS Biomedix's TransMID product for recurrent high-grade glioma in Japan

Intralesional CpG ODN evaluated in patients with basal cell carcinoma and melanoma

CCI-779 well tolerated and active in renal cell carcinoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...